Immune responses in the airways by nasal vaccination with systemic boosting against Pseudomonas aeruginosa in chronic lung disease

Vaccine

Volumn 27, Issue 21, 2009, Pages 2755-2759

  Sorichter, Stephan ^a   Baumann, Ulrich ^b   Baumgart, Astrid ^a   Walterspacher, Stephan ^a   von Specht, Bernd Ulrich ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Chronic obstructive lung disease; Cystic fibrosis; Mucosal vaccination; Outer membrane proteins; P. aeruginosa

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; OUTER MEMBRANE PROTEIN; PSEUDOMONAS VACCINE;

ADULT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; BACTERIAL PNEUMONIA; BRONCHIECTASIS; CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTIOCYTOSIS X; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ADMINISTRATION, INTRANASAL; ADULT; AGED; ANTIBODIES, VIRAL; CHRONIC DISEASE; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; LUNG DISEASES; MALE; MIDDLE AGED; NASAL MUCOSA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PSEUDOMONAS VACCINES;

EID: 64449088852     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.03.010     Document Type: Article

References (24)

1. Lusuardi M., Capelli A., Di Stefano A., Zaccaria S., Balbi B., and Donner C.F. Lower respiratory tract infections in chronic obstructive pulmonary disease outpatients with tracheostomy and persistent colonization by P. aeruginosa. Respir Med 97 11 (2003) 1205-1210
2. Rello J., and Torres A. Microbial causes of ventilator-associated pneumonia. Semin Respir Infect 11 1 (1996) 24-31
3. Valles J., Mesalles E., Mariscal D., del Mar Fernandez M., Pena R., Jimenez J.L., et al. A 7-year study of severe hospital-acquired pneumonia requiring ICU admission. Intensive Care Med 29 11 (2003) 1981-1988
4. Navon-Venezia S., Ben-Ami R., and Carmeli Y. Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Curr Opin Infect Dis 18 4 (2005) 306-313
5. Macia M.D., Blanquer D., Togores B., Sauleda J., Perez J.L., and Oliver A. Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob Agents Chemother 49 8 (2005) 3382-3386
6. Lang A.B., Rudeberg A., Schoni M.H., Que J.U., Furer E., and Schaad U.B. Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. Pediatr Infect Dis J 23 6 (2004) 504-510
7. Doring G., Meisner C., and Stern M. A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc Natl Acad Sci U S A 104 26 (2007) 11020-11025
8. Brandtzaeg P., Baekkevold E.S., Farstad I.N., Jahnsen F.L., Johansen F.E., Nilsen E.M., et al. Regional specialization in the mucosal immune system: what happens in the microcompartments?. Immunol Today 20 3 (1999) 141-151
9. Brandtzaeg P. Role of secretory antibodies in the defence against infections. Int J Med Microbiol 293 1 (2003) 3-15
10. Cripps A.W., Dunkley M.L., Clancy R.L., and Kyd J. Vaccine strategies against Pseudomonas aeruginosa infection in the lung. Behring Inst Mitt 98 (1997) 262-268
11. Boyaka P.N., Marinaro M., Vancott J.L., Takahashi I., Fujihashi K., Yamamoto M., et al. Strategies for mucosal vaccine development. Am J Trop Med Hyg 60 4 Suppl (1999) 35-45
12. von Specht B.U., Knapp B., Muth G., Broker M., Hungerer K.D., Diehl K.D., et al. Protection of immunocompromised mice against lethal infection with Pseudomonas aeruginosa by active or passive immunization with recombinant P. aeruginosa outer membrane protein F and outer membrane protein I fusion proteins. Infect Immun 63 5 (1995) 1855-1862
13. Mansouri E., Gabelsberger J., Knapp B., Hundt E., Lenz U., Hungerer K.D., et al. Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Infect Immun 67 3 (1999) 1461-1470
14. Mansouri E., Blome-Eberwein S., Gabelsberger J., Germann G., and von Specht B.U. Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients. FEMS Immunol Med Microbiol 37 2-3 (2003) 161-166
15. Larbig M., Mansouri E., Freihorst J., Tummler B., Kohler G., Domdey H., et al. Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Vaccine 19 17-19 (2001) 2291-2297
16. Gocke K., Baumann U., Hagemann H., Gabelsberger J., Hahn H., Freihorst J., et al. Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: comparison of a systemic vs. a mucosal booster schedule. FEMS Immunol Med Microbiol 37 2-3 (2003) 167-171
17. Baumann U., Mansouri E., and von Specht B. Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections. Vaccine 22 7 (2004) 840-847
18. Wu L., Estrada O., Zaborina O., Bains M., Shen L., Kohler J.E., et al. Recognition of host immune activation by Pseudomonas aeruginosa. Science 309 5735 (2005) 774-777
19. von Specht B.U., Gabelsberger J., Knapp B., Hundt E., Schmidt-Pilger H., Bauernsachs S., et al. Immunogenic efficacy of differently produced recombinant vaccines candidates against Pseudomonas aeruginosa infections. J Biotechnol 83 1-2 (2000) 3-12
20. Baumann U., Gocke K., Gewecke B., Freihorst J., and von Specht B.U. Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical phase I/II study. Respir Res 8 1 (2007) 57
21. Groenewegen K.H., and Wouters E.F.M. Bacterial infections in patients requiring admission for an acute exacerbation of COPD; a 1-year prospective study. Respir Med 97 7 (2003) 770-777
22. Pawar M., Mehta Y., Khurana P., Chaudhary A., Kulkarni V., and Trehan N. Ventilator-associated pneumonia: incidence, risk factors, outcome, and microbiology. J Cardiothorac Vasc Anesth 17 1 (2003) 22-28
23. Arnold H., Bumann D., Felies M., Gewecke B., Sorensen M., Gessner J.E., et al. Enhanced immunogenicity in the murine airway mucosa with an attenuated Salmonella live vaccine expressing OprF-OprI from Pseudomonas aeruginosa. Infect Immun 72 11 (2004) 6546-6553
24. Stevens T.L., Bossie A., Sanders V.M., Fernandez-Botran R., Coffman R.L., Mosmann T.R., et al. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 334 6179 (1988) 255-258